ATase Inhibitor Program

About Jace Biomedical

Jace Biomedical is pioneering a targeted approach to treat diseases caused by protein aggregation in the endoplasmic reticulum (ER). Its core technology involves small molecules that inhibit specific ER acetyltransferases (ATases), thereby selectively upregulating ER-specific autophagy (reticulophagy) to degrade toxic protein aggregates without inducing global cellular autophagy. The company is building a pipeline anchored by a lead program for Alzheimer's disease, with potential expansion into other neurodegenerative, metabolic, and rare diseases driven by similar proteotoxic mechanisms. JBI is a private, preclinical-stage company leveraging a novel mechanistic insight to address a significant unmet medical need across multiple indications.

About Jace Biomedical

Jace Biomedical is pioneering a targeted approach to treat diseases caused by protein aggregation in the endoplasmic reticulum (ER). Its core technology involves small molecules that inhibit specific ER acetyltransferases (ATases), thereby selectively upregulating ER-specific autophagy (reticulophagy) to degrade toxic protein aggregates without inducing global cellular autophagy. The company is building a pipeline anchored by a lead program for Alzheimer's disease, with potential expansion into other neurodegenerative, metabolic, and rare diseases driven by similar proteotoxic mechanisms. JBI is a private, preclinical-stage company leveraging a novel mechanistic insight to address a significant unmet medical need across multiple indications.

Therapeutic Areas

Other Alzheimer's Disease Drugs